Sign in

You're signed outSign in or to get full access.

Paul Gendron

Director at InfuSystem Holdings
Board

About Paul A. Gendron

Paul A. Gendron, age 63, is an independent director of InfuSystem Holdings, Inc., serving on the board since May 15, 2019 . A CPA with 30+ years at PricewaterhouseCoopers LLP (22 years as audit partner), he held leadership roles including North Texas Market Assurance Leader, U.S. Assurance Talent Transformation Leader, and Southwest Region Technology Practice Risk Management Leader; he holds a BBA in accounting from the University of Texas at Austin and served on its Accounting Advisory Council . The Board affirmatively determined his independence, including reviewing a short financial consulting engagement with the company in early 2019 and concluding it did not impair independent judgment . He qualifies as the Audit Committee’s “financial expert” under Item 407 of Regulation S‑K .

Past Roles

OrganizationRoleTenureCommittees/Impact
PricewaterhouseCoopers LLPClient Service Partner; North Texas Market Assurance Leader; U.S. Assurance Talent Transformation Leader; Southwest Region Technology Practice Risk Management Leader22 years as audit partner (part of 30+ years at PwC) Led assurance practice across multiple offices; governance, risk management, capital markets advisory
University of Texas at AustinAccounting Advisory Council MemberNot disclosed Advisory capacity
Various Non‑profitsBoard rolesNot disclosed Not disclosed

External Roles

OrganizationRoleStatusCommittees/Impact
Accounting Advisory Council, UT AustinMemberCurrent/unspecifiedAdvisory role
Non‑profit BoardsDirectorPrior/unspecifiedNot disclosed

Board Governance

  • Committee assignments:
    • Audit Committee: Chair; members include Gendron, Eichenbaum, Hundzinski, Huss; designated “financial expert”; 8 meetings in 2024 .
    • Compensation Committee: Member; co‑chairs are Boyd and Huss; 9 meetings in 2024 .
    • Nominating & Governance Committee: Not a member; 2 meetings in 2024 .
  • Board effectiveness and process:
    • The Board met 6 times in 2024; each director attended at least 75% of Board and committee meetings; independent directors held executive sessions at each regular meeting, presided by the independent Chairman .
    • Leadership structure separates CEO and independent Chairman, supporting oversight .
    • Audit oversight milestones under his chairmanship: transition to Deloitte as auditor in 2023 after a competitive process; prior auditor BDO reported no adverse opinions; material weaknesses identified in 2022/early 2023 were addressed through governance processes; the Audit Committee recommended inclusion of audited consolidated financial statements in the 2024 Form 10‑K .

Fixed Compensation

ComponentAmount (USD)Notes
2024 Fees Earned or Paid in Cash$77,936 Board and committee fees paid quarterly in arrears
Standard Cash Retainers (Policy)Board member: $50,000; Audit Chair: $20,000; Audit member: $10,000; Compensation Co‑Chair: $10,000; Compensation member: $5,000; Nominating Chair: $10,000; Nominating member: $5,000 Applied per role; Board compensation policy

Performance Compensation

Equity Vehicle2024 GrantExercise/Grant PriceVestingExpiration
Stock Options (Director annual grant)35,685 options $6.34 per share Typically vests over 1 year or immediately upon change in control under the 2021 Plan May 17, 2034 for 2024 grant
2024 Option Award Fair Value (Accounting)$97,416 ASC 718 fair value basis Time‑vested (no performance metrics) 10‑year term under Plan
  • Director equity awards are time‑based options without performance conditions; no RSUs/PSUs disclosed for directors in 2024 .

Other Directorships & Interlocks

  • No current public company directorships disclosed for Paul Gendron; prior non‑profit boards and UT Austin advisory council noted .
  • No related interlocks or commercial relationships disclosed; related‑party transactions: none reportable in 2023–2024 .

Expertise & Qualifications

  • Designated Audit Committee “financial expert”; CPA; extensive audit, risk management, governance, and capital markets experience with global companies .
  • Board governance capabilities emphasize audit project management, risk controls, and M&A/public offerings .

Equity Ownership

CategoryShares/UnitsDetail
Total Beneficial Ownership200,109 shares; <1% of outstanding Based on 21,016,415 shares outstanding on Mar 20, 2025
Directly Owned65,000 shares As of Mar 20, 2025
Options Exercisable or Exercisable within 60 Days135,109 shares As of Mar 20, 2025
Outstanding Options (12/31/2024)135,109 total; 99,424 exercisable Balance unexercisable as of 12/31/2024
Option Expirations (Legacy Lots)25,000 each expiring May 20, 2030; May 18, 2031; May 17, 2032; 24,424 expiring May 18, 2033; 35,685 expiring May 17, 2034 Director grant cadence across prior years
Hedging/PledgingCompany policy discourages hedging and prohibits pledging/margin; pre‑clearance required No pledging disclosed

Governance Assessment

  • Strengths

    • Independence affirmed; prior short consulting engagement reviewed and deemed not impairing independence .
    • As Audit Chair and designated “financial expert,” he led a robust audit oversight process, including auditor transition and addressing previously disclosed material weaknesses, supporting investor confidence in financial reporting .
    • High engagement indicated by committee activity (Audit: 8 meetings; Compensation: 9; Board: 6) and directors’ attendance at least 75% .
    • Ownership alignment through meaningful option holdings; anti‑hedging/anti‑pledging policies reduce misalignment risk .
  • Watch items / potential red flags

    • 2024 Say‑on‑Pay earned 53% support, signaling shareholder dissatisfaction with pay practices; however, the Compensation Committee (of which Gendron is a member) conducted outreach (~69% of shares contacted; ~22% engaged/noted) and implemented 2025 changes (STI metrics shifted to 50% AEBITDA/50% revenue; PSU weight increased to 50%; RSU vesting moved to ratable over three years; PSU period extended to 3 years with relative TSR to Russell 2000), showing responsiveness .
    • Equity overhang: if shareholders approve the 2021 Plan amendment, fully diluted overhang would be ~20.2% (increase of 4.8%), which some investors may view as dilutive; rationale and share usage considerations were disclosed .
  • Related‑party/conflicts

    • No related‑party transactions reportable in 2023–2024; Board/Audit Committee pre‑approve any such transactions per policy .
    • Insider Trading Policy restricts hedging/pledging; Clawback adopted for executives and plan‑level recoupment rights for awards, mitigating misconduct risk .